Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 826

Sort by

Sort Order Select

Journal Articles

bcr3 PML-RARA : short fusion, small blasts!

Moe R. Takeda, Sandeep Gurbuxani

Blood (2021) 137 (19): 2708.

https://doi.org/10.1182/blood.2021010965

Published: 2021

Journal Articles

A PML/RARα direct target atlas redefines transcriptional deregulation in acute promyelocytic leukemia

Yun Tan, Xiaoling Wang, Huan Song, Yi Zhang, Rongsheng Zhang, Shufen Li, Wen Jin, Saijuan Chen, Hai Fang, Zhu Chen, Kankan Wang

Blood (2021) 137 (11): 1503–1516.

https://doi.org/10.1182/blood.2020005698

Published: 2021

Includes: Supplemental data

Journal Articles

PML-RARα: changing myeloid networks

Scott C. Kogan

Blood (2021) 137 (11): 1439–1440.

https://doi.org/10.1182/blood.2020008849

Published: 2021

Journal Articles

Integrated Transcriptomic and Genomic Sequencing Identifies Prognostic Constellations of Driver Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Ilaria Iacobucci, PhD, Manja Meggendorfer, PhD, Niroshan Nadarajah, Stanley Pounds, PhD, Lei Shi, PhD, Chunxu Qu, PhD, Constance Baer, PhD, Claudia Haferlach, MD, Wolfgang Kern, MD, Charles G. Mullighan, MBBS, MD, Torsten Haferlach, MD

Blood (2019) 134 (Supplement_2): LBA-4.

https://doi.org/10.1182/blood-2019-132746

Published: 2019

Journal Articles

Efficacy and Safety of Daily All-Trans Retinoic Acid Monotherapy As Maintenance Therapy for Acute Promyelocytic Leukemia

Yoo Jin Lee, MD PhD, Seo-Yeon Ahn, MD, Jae-Cheol Jo, MD PhD, Yunsuk Choi, MD, Ji Hyun Lee, MD PhD

Blood (2019) 134 (Supplement_1): 3898.

https://doi.org/10.1182/blood-2019-125671

Published: 2019

Journal Articles

New Insights into PLZF/Rara Mechanism during APL Onset: EZH2 on the Road

Mathilde Poplineau, Nadine Platet, PhD, Lia N'Guyen, Shuhei Koide, PhD, Julien Vernerey, PhD, Yaeko Nakajima-Takagi, PhD, Motohiko Oshima, PhD, Atsushi Iwama, MD PhD, Estelle Duprez, PhD

Blood (2019) 134 (Supplement_1): 3761.

https://doi.org/10.1182/blood-2019-125509

Published: 2019

Journal Articles

Value of Minimal Residual Disease (MRD) Monitoring Using Real-Time Quantitative PCR in Patients with Acute Promyelocytic Leukemia (APL) Treated with ATRA, ATO, +/- GO

Jorge Cortes, MD, Hagop M. Kantarjian, MD, Tapan M. Kadia, MD, Guillermo Garcia-Manero, MD, Elias Jabbour, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Nicholas J. Short, MD, Yesid Alvarado, MD, Musa E. Yilmaz, MD, Naval G. Daver, MD, David McCue, Sherry A. Pierce, BSN, BA, Jorge E. Cortes, MD, Farhad Ravandi, MD

Blood (2019) 134 (Supplement_1): 3851.

https://doi.org/10.1182/blood-2019-124599

Published: 2019

Journal Articles

Oral Arsenic Trioxide, ATRA and Ascorbic Acid (AAA) Maintenance Following First Complete Remission in Acute Promyelocytic Leukemia - Long-Term Data and Unique Prognostic Indicators

Harinder Gill, FRCP, FRCPath, Rita Yim, PhD, Cyrus R Kumana, FRCP, Yok-Lam Kwong, MD

Blood (2019) 134 (Supplement_1): 3853.

https://doi.org/10.1182/blood-2019-125185

Published: 2019

Journal Articles

Clinical and Functional Studies Reveal That TP73 Isoforms Levels Are Associated with Prognosis and RA-Resistance in Acute Promyelocytic Leukemia

Blood (2019) 134 (Supplement_1): 2719.

https://doi.org/10.1182/blood-2019-131211

Published: 2019

Journal Articles

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study

Anas Younes, MD, John M Burke, MD, Bruce D. Cheson, MD, Catherine Diefenbach, MD, Silvia Ferrari, MD, Uwe H Hahn, MD, Eliza A Hawkes, Cyrus Khan, MD, Izidore S. Lossos, MD, Gerardo Musuraca, MD PhD, Monica Tani, Umberto Vitolo, Sam Lung Sang Yuen, MBBS,FRCPA,FRACP, Aparna Raval, PhD, Mahesh R. Shivhare, PhD, Tina G Nielsen, MD PhD, Gila Sellam, PhD, Jeff P. Sharman, MD

Blood (2019) 134 (Supplement_1): 2874.

https://doi.org/10.1182/blood-2019-123368

Published: 2019

Journal Articles

Brentuximab Vedotin in Combination with Nivolumab, Doxorubucin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma

Judah Friedman, MD, Hun Ju Lee, MD, Linda Ho, Ian W. Flinn, MD PhD

Blood (2019) 134 (Supplement_1): 2836.

https://doi.org/10.1182/blood-2019-122969

Published: 2019

Journal Articles

Reduced SLIT2 Are Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in APL Cells

Isabel Weinhäuser, MSc, Diego A Pereira-Martins, MSc, Luíse A A Simões, BSc, César Alexander Ortiz Rojas, BSc, Thiago Mantello Bianco, MSc, Cleide Lucia Silva, MSc, Mariane Cristina Do Nascimento, BSc, Lorena Lobo Figueiredo-Pontes, MD PhD, Antonio R. Lucena-Araujo, PhD, Eduardo M Rego, MD PhD

Blood (2019) 134 (Supplement_1): 5165.

https://doi.org/10.1182/blood-2019-131496

Published: 2019

Journal Articles

BCR-ABL1+ AML De Novo and CBF-Leukemia at Relapse: Game of Clones

Olga Kulemina, MD, Nadia Siordia, MD, Konstantin Bogdanov, PhD, Julia Alexeeva, MD PhD, Larisa Girshova, MD PhD, Elza Lomaia, MD PhD, Andrey Zaritskey, MD PhD

Blood (2019) 134 (Supplement_1): 5138.

https://doi.org/10.1182/blood-2019-129815

Published: 2019

Journal Articles

Local Field Radiotherapy Induced Therapy Related Myeloid Neoplasms and Bone Marrow Suppression

Dina Sameh Soliman, MD MB, MMSc, Ahmad Al-Sabbagh, MD, Firyal Ibrahim, MD, Halima El-Omri, MD, Mohamed A Yassin, MBBS, MSc, Aliaa Amer, MD

Blood (2019) 134 (Supplement_1): 5113.

https://doi.org/10.1182/blood-2019-131683

Published: 2019

Journal Articles

Improved Outcomes of All-Trans-Retinoic Acid and Arsenic Trioxide Plus Idarubicin As a Frontline Treatment in Adult Patients with Acute Promyelocytic Leukemia

Shiwei Yang, Zunmin Zhu, Xiaojian Zhu, Yicheng Zhang

Blood (2019) 134 (Supplement_1): 5088.

https://doi.org/10.1182/blood-2019-128602

Published: 2019

Journal Articles

CUDC-101 Overcomes Arsenic Trioxide Resistance Via Caspase-Dependent PML-Rarα Degradation in Acute Promyelocytic Leukemia

Tianzhuo Zhang, Jishi Wang, PhD

Blood (2019) 134 (Supplement_1): 5054.

https://doi.org/10.1182/blood-2019-131618

Published: 2019

Journal Articles

The Presence of Minimal Residual Disease, As Determined By Highly Sensitive Quantitation of NPM1 -Mutatation, Provided Powerful Prognostic Information in Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 5097.

https://doi.org/10.1182/blood-2019-127725

Published: 2019

Journal Articles

Unexpected Concomitance of BCR-ABL and PML-Rarα Leukemia - Three-Year Follow-up

Caique Pereira de Moura Martins, MDcal Student, João Vítor Ternes Rech, MDcal Student, Lee I-Ching, MD, Giovanna Steffenello Durigon, MD, Joanita Angela Del Moral, MD, Mirella Rodrigues Oliveira, MD, Bruno Vieira Dias, Maria Claudia Santos, PhD, Andressa Oliveira Martin Wagner, André Guedes Vieira

Blood (2019) 134 (Supplement_1): 5038.

https://doi.org/10.1182/blood-2019-132259

Published: 2019

Journal Articles

Pediatric Acute Promyelocytic Leukemia in Brazil: Epidemiology, Molecular Features, and Importance of GST-Theta 1 in Chemotherapy Response and Outcome

Francianne G. Andrade, MSc, PhD, Suellen V. M. Feliciano, MSc, PhD, Ingrid Sardou-Cezar, Gisele D. Brisson, MSc, Filipe V. S. Bueno, MSc, Danielle T. Vianna, MD MSc, Eugênia Terra-Granado, MSc, PhD, Ilana Z. Renault, Marceli O. Santos, MSc, PhD, Elda P. Noronha, MSc, PhD, Joseph L. Wiemels, PhD, Maria S. Pombo-de-Oliveira, MD PhD

Blood (2019) 134 (Supplement_1): 5187.

https://doi.org/10.1182/blood-2019-131529

Published: 2019

Journal Articles

Molecular Karyotyping Combined with FISH Offers an Alternative to Chromosome Banding Analysis for Diagnostic Evaluation of Genome Complexity in Acute Myeloid Leukemia

A Borsatti, Elisabeth P. Nacheva, MD PhD

Blood (2019) 134 (Supplement_1): 5188.

https://doi.org/10.1182/blood-2019-131983

Published: 2019

NARROW

bcr3 PML-RARA : short fusion, small blasts!

A PML/RARα direct target atlas redefines transcriptional deregulation in acute promyelocytic leukemia

PML-RARα: changing myeloid networks

Integrated Transcriptomic and Genomic Sequencing Identifies Prognostic Constellations of Driver Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Efficacy and Safety of Daily All-Trans Retinoic Acid Monotherapy As Maintenance Therapy for Acute Promyelocytic Leukemia

New Insights into PLZF/Rara Mechanism during APL Onset: EZH2 on the Road

Value of Minimal Residual Disease (MRD) Monitoring Using Real-Time Quantitative PCR in Patients with Acute Promyelocytic Leukemia (APL) Treated with ATRA, ATO, +/- GO

Oral Arsenic Trioxide, ATRA and Ascorbic Acid (AAA) Maintenance Following First Complete Remission in Acute Promyelocytic Leukemia - Long-Term Data and Unique Prognostic Indicators

Clinical and Functional Studies Reveal That TP73 Isoforms Levels Are Associated with Prognosis and RA-Resistance in Acute Promyelocytic Leukemia

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study

Brentuximab Vedotin in Combination with Nivolumab, Doxorubucin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma

Reduced SLIT2 Are Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in APL Cells

BCR-ABL1+ AML De Novo and CBF-Leukemia at Relapse: Game of Clones

Local Field Radiotherapy Induced Therapy Related Myeloid Neoplasms and Bone Marrow Suppression

Improved Outcomes of All-Trans-Retinoic Acid and Arsenic Trioxide Plus Idarubicin As a Frontline Treatment in Adult Patients with Acute Promyelocytic Leukemia

CUDC-101 Overcomes Arsenic Trioxide Resistance Via Caspase-Dependent PML-Rarα Degradation in Acute Promyelocytic Leukemia

The Presence of Minimal Residual Disease, As Determined By Highly Sensitive Quantitation of NPM1 -Mutatation, Provided Powerful Prognostic Information in Acute Myeloid Leukemia

Unexpected Concomitance of BCR-ABL and PML-Rarα Leukemia - Three-Year Follow-up

Pediatric Acute Promyelocytic Leukemia in Brazil: Epidemiology, Molecular Features, and Importance of GST-Theta 1 in Chemotherapy Response and Outcome

Molecular Karyotyping Combined with FISH Offers an Alternative to Chromosome Banding Analysis for Diagnostic Evaluation of Genome Complexity in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only